Businesswire News Releases

Sep 18, 2021 22:50 ET
Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has issued a new task order under its current contract with the company, with a value of up to approximately $10 million. The company also announced that it has received, so far in Q3, more than $25M in orders from its oncology customers, a new record. Together these orders allow the company to reconfirm its total revenue outlook for 2021, with oncology revenue growth now projected to be at least 50% a...
Sep 18, 2021 22:12 ET
“We’ve run out of staff. Kenney’s fourth wave is collapsing the system.” Rory Gill, President CUPE Alberta
The leaders of Alberta’s largest health care unions are calling on Premier Jason Kenney to ask the federal government to immediately deploy the military, the Red Cross and all other available medical resources from across the country to assist the province’s overwhelmed hospitals....
Sep 18, 2021 21:13 ET
Epsilyte Moving Expandable Polystyrene (EPS) Prices up to Keep Pace With Rising Feedstock Costs
Epsilyte, a leading North American producer of Expandable Polystyrene (EPS), will increase the price of all grades of EPS by $0.05/lb., effective October 1, 2021 or as contracts permit. Escalating feedstock costs necessitate this adjustment....
Sep 18, 2021 11:30 ET
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting....
Sep 18, 2021 11:30 ET
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting....
Sep 18, 2021 09:34 ET
 Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has receiv...
Sep 18, 2021 09:05 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented today in a Presidential Symposium at the ...
Sep 18, 2021 09:05 ET
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
Detailed positive results from the head-to-head DESTINY-Breast03 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca HER2 directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus tr...
Sep 18, 2021 09:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with KEYTRUDA, Merck’s anti-PD-1 therapy, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial’s primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma; KEYTRUDA is the first anti-PD-1 therapy to demonstrate this....
Sep 18, 2021 09:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persisten
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the full results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract #LBA2). These data were also simultaneously published in the New England Journal of Medicine. This is the first combination regimen with an anti-PD-1/PD-L1...
Sep 18, 2021 08:45 ET
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily. These results showed a confirmed objective response rate (ORR) of 44%, as evaluated centrally by an independent image review committee using RECIST 1.1 criteria. The data was presented as a late ...
Sep 18, 2021 07:30 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
Detailed primary results from the positive Phase II DESTINY-Lung01 trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2021 and simultaneously published in
Sep 18, 2021 07:30 ET
ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Detailed primary results from the positive, pivotal DESTINY-Lung01 phase 2 trial of ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca HER2 directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously-treated patient...
Sep 18, 2021 07:30 ET
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer (CRPC). Cohort 6 included patients with metastatic CRPC who had been previously treated wit...
Sep 18, 2021 07:00 ET
Pipedrive Teams Up With World Cleanup Day as a Supporting Partner to Help Rid Our Planet of Trash
Pipedrive, the leading CRM for sales and marketing teams, announced today that the company has teamed up with
Sep 17, 2021 22:50 ET
COINBASE GLOBAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Coi
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 20, 2021 to file lead plaintiff applications in securities class action lawsuits against Coinbase Global Inc. (NasdaqGS: COIN), if they purchased the Company’s shares issued in connection with its April 2021 Direct Offering (the "Offering"). These actions are pending in the United States District Court for the Northern District of California....
Sep 17, 2021 22:50 ET
EHEALTH INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of eHealth, Inc. - EHTH
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into eHealth, Inc. (NasdaqGS: EHTH)....
Sep 17, 2021 22:50 ET
FACEBOOK INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Facebook, Inc. - FB
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Facebook, Inc. (NasdaqGS: FB)....
Sep 17, 2021 19:26 ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against CorMedix Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired CorMedix securities between October 16, 2019 and May 13, 2021, both dates inclusive (the “Class Period”). Investors have until September 20, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit....